Olowo-Okere Ahmed, Yacouba Abdourahamane
PharmD, PhD, Usmanu Danfodiyo University, Faculty of Pharmaceutical Sciences, P.M.B. 2346, Sokoto, Nigeria.
MD, Université Abdou Moumouni, Faculté des Sciences de la Santé, P.M.B. 10896, Niamey, Niger.
Germs. 2020 Dec 28;10(4):367-379. doi: 10.18683/germs.2020.1229. eCollection 2020 Dec.
Updated and comprehensive data on the mechanism underlying colistin resistance is lacking in Africa.
Herein, we aimed to review available literature on the molecular mechanisms of colistin resistance in Africa. PubMed, Google Scholar, and African Journal online databases were searched on the 15th of January 2020 for original research articles that reported mechanisms of colistin resistance in any of the 54 African countries.
Of the 1473 studies identified through initial database search, 36 met the inclusion criteria. Colistin resistance was mostly observed in isolated from human clinical samples. Plasmid-mediated colistin resistance mechanism (26; 72.2%) was the most frequently reported resistance mechanism. About three-quarters (27; 75.0%) of the 36 studies were done in North Africa. In this zone, the mobilized colistin resistance () genes were mostly detected in harboring three plasmid types, , , and , from animal samples (n=9; 42.8%). Of the six studies performed in Southern Africa, four reported mostly detected from human samples (n=2; 50.0%) in isolates carrying , , and with diverse range of STs. One hitherto unknown mutation, the mutation in the gene was detected in colistin resistant isolates in this region, which was absent in colistin susceptible isolates. In West and Central Africa, two and one studies, respectively, reported gene exclusively in isolates.
Transferable plasmid mediated colistin resistance is rapidly emerging in Africa with as the predominant genetic variant in human, animals, and environmental samples.
非洲缺乏关于黏菌素耐药性潜在机制的最新且全面的数据。
在此,我们旨在综述非洲黏菌素耐药性分子机制的现有文献。2020年1月15日,我们在PubMed、谷歌学术和非洲期刊在线数据库中搜索了关于54个非洲国家中任何一个国家黏菌素耐药机制的原始研究文章。
通过初步数据库检索确定的1473项研究中,有36项符合纳入标准。黏菌素耐药性大多在从人类临床样本中分离出的菌株中观察到。质粒介导的黏菌素耐药机制(26项;72.2%)是最常报道的耐药机制。36项研究中约四分之三(27项;75.0%)在北非进行。在该地区,可移动黏菌素耐药(mcr)基因大多在携带三种质粒类型IncX4、IncI2和IncFIB的动物样本(n = 9;42.8%)中检测到。在南部非洲进行的六项研究中,四项报告mcr大多在携带IncFIB、IncN和IncX1且具有多种ST型的大肠埃希菌分离株(n = 2;50.0%)的人类样本中检测到。在该地区的黏菌素耐药分离株中检测到一个迄今未知的突变,即mgrB基因中的突变,而在黏菌素敏感分离株中不存在。在西非和中非,分别有两项和一项研究报告mcr基因仅在肺炎克雷伯菌分离株中存在。
在非洲,可转移质粒介导的黏菌素耐药性正在迅速出现,mcr作为人类、动物和环境样本中的主要遗传变体。